April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 29, 2025

Foley Catheter Management: New Best Practices, Pitfalls

Foley catheter use is associated with a wide range of complications, from infections to urethral erosion.

Conexiant

April 29, 2025

Flu Shots Linked to Temporary Menstrual Changes

Study shows small, temporary cycle length increases after vaccination

Conexiant

April 29, 2025

RadSearch Transforms Radiology Report Retrieval 

RadSearch could enhance radiologists' ability to find precedent cases.

Conexiant

April 28, 2025

More Menopause Symptoms, Greater Cognitive Risk

Study demonstrates dose-dependent relationship: each additional menopausal symptom associated with poorer cognitive function and increased behavioral changes in later life.

Conexiant

April 25, 2025

Multidimensional Sleep Health Affects Heart

Sleep is not a unitary physiologic experience, the AHA states in its new scientific statement, which redefines how physicians should assess sleep’s impact on cardiometabolic health.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 22, 2025

Dual Therapy Lowers Death Risk in Diabetes Study

A large study found that combining GLP-1 receptor agonists with thiazolidinediones significantly reduced death and heart risks in patients with type 2 diabetes.

Conexiant

April 21, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.

The ASCO Post